MIRA

MIRA Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Other
Website mirapharmaceuticals.com
Employees(FY) -
ISIN US60458C1045

Performance

-20.94%

+15.0%

-28.93%

+93.13%

+20.48%

YTD

-72.8%

Profile

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.

Advanced Technical Analysis

Technical Analysis of MIRA 2024-11-20

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 16 indicating strong downward pressure, the Oscillators Score at 43 suggesting a neutral stance, and the Technical Score at 30 reinforcing the bearish outlook. This combination points to a challenging market environment, with potential for further declines...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of MIRA

Stock Rank

Recent News & Updates

2024-11-19 18:44
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site(Accesswire)
2024-10-28 22:57
MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials(Yahoo Finance)
2024-10-28 01:41
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain(Yahoo Finance)
2024-10-27 19:30
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain(Accesswire)
2024-10-27 05:34
Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024(Yahoo Finance)
2024-10-20 19:30
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study(Accesswire)
2024-09-26 19:30
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024(Accesswire)
2024-09-18 21:00
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025(Newsdirect)
2024-09-17 19:00
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025(Accesswire)
2024-09-10 19:30
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA(Accesswire)
2024-08-25 20:00
MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study(Accesswire)
2024-08-18 19:30
MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End(Accesswire)
2024-08-11 20:30
Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman(Globenewswire)
2024-08-11 20:00
MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor(Accesswire)
2024-08-04 21:40
PayPal, Kellanova upgraded: Wall Street's top analyst calls(Yahoo Finance)
2024-07-25 03:24
Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data(Yahoo Finance)
2024-07-24 19:00
MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action(Accesswire)
2024-07-22 00:56
Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today?(Investorplace)
2024-07-21 22:31
Nano-Cap MIRA Pharmaceuticals' Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders(Yahoo Finance)
2024-07-21 20:00
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance(Accesswire)
2024-07-14 19:00
Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC(Accesswire)
2024-06-23 20:30
MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing(Prnewswire)
2024-06-09 20:30
Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year(Prnewswire)
2024-05-28 20:45
Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance(Prnewswire)
2024-05-20 20:45
MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog(Prnewswire)
2024-05-19 20:00
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog(Prnewswire)
2024-05-13 09:53
MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q1 2024(Investorplace)
2024-04-01 20:00
Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission(Prnewswire)
2024-04-01 02:53
MIRA Stock Earnings: Mira Pharmaceuticals Beats EPS for Q4 2023(Investorplace)
2024-03-20 23:04
MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor(Prnewswire)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.